High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Nature Medicine2015Vol. 21(11), pp. 1318–1325
Citations Over TimeTop 1% of 2015 papers
Hui Gao, Joshua M. Korn, Stéphane Ferretti, John E. Monahan, Youzhen Wang, Mallika Singh, Chao Zhang, Christian Schnell, Guizhi Yang, Yun Zhang, O. Alejandro Balbin, Stéphanie Barbé, Hongbo Cai, Fergal Casey, Susmita Chatterjee, Derek Y. Chiang, Shannon Chuai, Shawn Cogan, Scott D. Collins, Ernesta Dammassa, Nicolas Ebel, Millicent Embry, John Green, Audrey Kauffmann, Colleen Kowal, Rebecca Leary, Joseph Lehár, Ying Liang, Alice Loo, Edward Lorenzana, E. Robert McDonald, Margaret E. McLaughlin, Jason J. Merkin, Ronald A. Meyer, Tara L. Naylor, Montesa Patawaran, Anupama Reddy, Claudia Röelli, David A. Ruddy, Fernando Salangsang, Francesca Santacroce, Angad Singh, Yan Tang, Walter Tinetto, Sonja Tobler, Roberto Velazquez, K. Venkatesan, Fabian Von Arx, Hui Qin Wang, Zongyao Wang, Marion Wiesmann, Daniel F. Wyss, Fiona Xu, Hans Bitter, Peter Atadja, Emma Lees, Francesco Hofmann, En Li, Nicholas Keen, Robert Cozens, Michael Rugaard Jensen, Nancy Pryer, Juliet Williams, William R. Sellers
Related Papers
- → Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models(2019)241 cited
- → The genetics of drug efficacy: opportunities and challenges(2016)115 cited
- → Imaging biomarkers as surrogate endpoints for drug development(2006)27 cited
- → Drug development for pediatric neurogenic bladder dysfunction: Dosing, endpoints, and study design(2014)5 cited
- → Biomarkers and Surrogate Markers in Drug Development(2010)